{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T10:37:05Z","timestamp":1793270225535,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00415-026-14169-2","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:00:56Z","timestamp":1790686856000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Scleromyxedema-Associated Myopathy and Vacuolar Myopathy with Monoclonal Gammopathy and Stiffness (VAMMGAS) as manifestations of Monoclonal Gammopathy of Clinical Significance (MGCS): a disease spectrum between autophagy dysfunction and inflammation"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9335-1218","authenticated-orcid":false,"given":"Tommaso","family":"Nicoletti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Benveniste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Battistella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibault","family":"Mahevas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Arnulf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Stojkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Staedler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Maisonobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Letournel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Malfatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marguerite","family":"Vignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Nadaj-Pakleza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Labella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Lacene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Brochier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresinha","family":"Evangelista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Leonard-Louis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"14169_CR1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000214101","volume":"105","author":"P Soontrapa","year":"2025","unstructured":"Soontrapa P, Jones FJS, Milone M et al (2025) Clinicopathologic features, pathogenesis, and treatment of monoclonal gammopathy-associated myopathies. Neurology 105:e214101. https:\/\/doi.org\/10.1212\/WNL.0000000000214101","journal-title":"Neurology"},{"key":"14169_CR2","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1182\/blood-2018-04-839480","volume":"132","author":"JP Fermand","year":"2018","unstructured":"Fermand JP, Bridoux F, Dispenzieri A et al (2018) Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood 132:1478\u20131485. https:\/\/doi.org\/10.1182\/blood-2018-04-839480","journal-title":"Blood"},{"key":"14169_CR3","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.nmd.2017.05.007","volume":"27","author":"M Wang","year":"2017","unstructured":"Wang M, Lei L, Chen H et al (2017) Monoclonal gammopathy with both nemaline myopathy and amyloid myopathy. Neuromuscul Disord 27:942\u2013946. https:\/\/doi.org\/10.1016\/j.nmd.2017.05.007","journal-title":"Neuromuscul Disord"},{"key":"14169_CR4","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.nmd.2022.03.006","volume":"32","author":"O Moshe-Lilie","year":"2022","unstructured":"Moshe-Lilie O, Banks G, Medvedova E, Masri A, Chahin N (2022) Coexisting sporadic late-onset nemaline myopathy and AL amyloid myopathy - incidental or related? Neuromuscul Disord 32:533\u2013538. https:\/\/doi.org\/10.1016\/j.nmd.2022.03.006","journal-title":"Neuromuscul Disord"},{"key":"14169_CR5","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jaad.2013.01.007","volume":"69","author":"F Rongioletti","year":"2013","unstructured":"Rongioletti F, Merlo G, Cinotti E et al (2013) Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients. J Am Acad Dermatol 69:66\u201372. https:\/\/doi.org\/10.1016\/j.jaad.2013.01.007","journal-title":"J Am Acad Dermatol"},{"key":"14169_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/0190-9622(95)90007-1","volume":"33","author":"AM Dinneen","year":"1995","unstructured":"Dinneen AM, Dicken CH (1995) Scleromyxedema. J Am Acad Dermatol 33:37\u201343. https:\/\/doi.org\/10.1016\/0190-9622(95)90007-1","journal-title":"J Am Acad Dermatol"},{"key":"14169_CR7","first-page":"153","volume":"2","author":"K James","year":"1967","unstructured":"James K, Fudenberg H, Epstein WL, Shuster J (1967) Studies on a unique diagnostic serum globulin in papular mucinosis (lichen myxedematosus). Clin Exp Immunol 2:153\u2013166","journal-title":"Clin Exp Immunol"},{"key":"14169_CR8","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1111\/jdv.19937","volume":"38","author":"R Knobler","year":"2024","unstructured":"Knobler R, Geroldinger-Simic M, Kreuter A et al (2024) Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, part 2: scleromyxoedema and scleroedema. J Eur Acad Dermatol Venereol 38:1281\u20131299. https:\/\/doi.org\/10.1111\/jdv.19937","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"14169_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/MD.0b013e3181630835","volume":"87","author":"M Blum","year":"2008","unstructured":"Blum M, Wigley FM, Hummers LK (2008) Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG). Medicine (Baltimore) 87:10\u201320. https:\/\/doi.org\/10.1097\/MD.0b013e3181630835","journal-title":"Medicine (Baltimore)"},{"key":"14169_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/jca.22153","volume":"39","author":"MH Lanehart","year":"2024","unstructured":"Lanehart MH, Johnson ES, Aqui NA (2024) Therapeutic plasma exchange for the symptomatic treatment of scleromyxedema: a case report and literature review. J Clin Apher 39:e22153. https:\/\/doi.org\/10.1002\/jca.22153","journal-title":"J Clin Apher"},{"key":"14169_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-237170","volume":"13","author":"JM Larios","year":"2020","unstructured":"Larios JM, Ciuro J, Sam Varghese T, Lyons SE (2020) Successful treatment of dermato-neuro syndrome with plasmapheresis. BMJ Case Rep 13:e237170. https:\/\/doi.org\/10.1136\/bcr-2020-237170","journal-title":"BMJ Case Rep"},{"key":"14169_CR12","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1007\/s00415-019-09379-w","volume":"266","author":"A Soulages","year":"2019","unstructured":"Soulages A, Tang HM, Pham-Ledard A et al (2019) Myopathy and scleromyxedema. J Neurol 266:2051\u20132059. https:\/\/doi.org\/10.1007\/s00415-019-09379-w","journal-title":"J Neurol"},{"key":"14169_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1365-2133.1975.tb06786.x","volume":"93","author":"R Kubba","year":"1975","unstructured":"Kubba R, Champion RH (1975) Scleromyxoedema. Br J Dermatol 93:36\u201338. https:\/\/doi.org\/10.1111\/j.1365-2133.1975.tb06786.x","journal-title":"Br J Dermatol"},{"key":"14169_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70026","volume":"32","author":"K Staedler","year":"2025","unstructured":"Staedler K, Allenbach Y, Salort-Campana E et al (2025) Vacuolar myopathy with monoclonal gammopathy and stiffness (VAMMGAS). Eur J Neurol 32:e70026. https:\/\/doi.org\/10.1111\/ene.70026","journal-title":"Eur J Neurol"},{"key":"14169_CR15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.91393","volume":"17","author":"MR Belkhribchia","year":"2025","unstructured":"Belkhribchia MR, Toua T, Lobrinus JA, Vallat JM, Salmaoui J (2025) Monoclonal gammopathy of clinical significance-associated glycogen storage myopathy: a novel acquired muscle disease. Cureus 17:e91393. https:\/\/doi.org\/10.7759\/cureus.91393","journal-title":"Cureus"},{"key":"14169_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70557","volume":"33","author":"FJS Jones","year":"2026","unstructured":"Jones FJS, Cheema I, Laughlin RS, Muchtar E, Liewluck T (2026) Concurrent sporadic late-onset nemaline myopathy and an excessive glycogen accumulation associated with monoclonal gammopathy. Eur J Neurol 33:e70557. https:\/\/doi.org\/10.1111\/ene.70557","journal-title":"Eur J Neurol"},{"key":"14169_CR17","first-page":"26","volume":"33","author":"E von Nagy","year":"1962","unstructured":"von Nagy E et al (1962) Gleichzeitiges vorkommen von hashimotos struma, dermatomyositis und skleromyxoedem. Z Haut Geschlechtskr 33:26\u201329","journal-title":"Z Haut Geschlechtskr"},{"key":"14169_CR18","first-page":"109","volume":"147","author":"BL Johnson","year":"1973","unstructured":"Johnson BL, Horowitz IR, Charles CR, Cooper DL (1973) Dermatomyositis and lichen myxedematosus. A clinical, histopathological and electron microscopic study. Dermatologica 147:109\u2013122","journal-title":"Dermatologica"},{"key":"14169_CR19","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1093\/ajcp\/69.4.446","volume":"69","author":"MA Verity","year":"1978","unstructured":"Verity MA, Toop J, McAdam LP, Pearson CM (1978) Scleromyxedema myopathy. Histochemical and electron microscopic observations. Am J Clin Pathol 69:446\u2013451. https:\/\/doi.org\/10.1093\/ajcp\/69.4.446","journal-title":"Am J Clin Pathol"},{"key":"14169_CR20","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1001\/archderm.1979.04010030003002","volume":"115","author":"RB Harris","year":"1979","unstructured":"Harris RB, Perry HO, Kyle RA, Winkelmann RK (1979) Treatment of scleromyxedema with melphalan. Arch Dermatol 115:295\u2013299","journal-title":"Arch Dermatol"},{"key":"14169_CR21","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/j.1445-5994.1986.tb01180.x","volume":"16","author":"JM Harvey","year":"1986","unstructured":"Harvey JM, Zilko PJ, Cheah PS, Mastaglia FL, Ojeda VJ (1986) Scleromyxedema and inflammatory myopathy: a clinicopathologic study of three patients. Aust N Z J Med 16:329\u2013335. https:\/\/doi.org\/10.1111\/j.1445-5994.1986.tb01180.x","journal-title":"Aust N Z J Med"},{"key":"14169_CR22","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/art.1780290716","volume":"29","author":"EJ Fudman","year":"1986","unstructured":"Fudman EJ, Golbus J, Ike RW (1986) Scleromyxedema with systemic involvement mimics rheumatic diseases. Arthritis Rheum 29:913\u2013917. https:\/\/doi.org\/10.1002\/art.1780290716","journal-title":"Arthritis Rheum"},{"key":"14169_CR23","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/art.1780311115","volume":"31","author":"DJ Helfrich","year":"1988","unstructured":"Helfrich DJ, Walker ER, Martinez AJ, Medsger TA Jr (1988) Scleromyxedema myopathy: case report and review of the literature. Arthritis Rheum 31:1437\u20131441. https:\/\/doi.org\/10.1002\/art.1780311115","journal-title":"Arthritis Rheum"},{"key":"14169_CR24","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/j.1365-4362.1989.tb02437.x","volume":"28","author":"AO Harris","year":"1989","unstructured":"Harris AO, Altman AR, Tschen JA, Wolf JE Jr (1989) Scleromyxedema. Int J Dermatol 28:661\u2013667. https:\/\/doi.org\/10.1111\/j.1365-4362.1989.tb02437.x","journal-title":"Int J Dermatol"},{"key":"14169_CR25","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/j.1365-4362.1989.tb02436.x","volume":"28","author":"MJ Rothe","year":"1989","unstructured":"Rothe MJ, Rivas R, Gould E, Kerdel FA (1989) Scleromyxedema and severe myositis. Int J Dermatol 28:657\u2013660. https:\/\/doi.org\/10.1111\/j.1365-4362.1989.tb02436.x","journal-title":"Int J Dermatol"},{"key":"14169_CR26","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/0190-9622(91)70132-L","volume":"24","author":"BM Hisler","year":"1991","unstructured":"Hisler BM, Savoy LB, Hashimoto K (1991) Improvement of scleromyxedema associated with isotretinoin therapy. J Am Acad Dermatol 24:854\u2013857. https:\/\/doi.org\/10.1016\/0190-9622(91)70132-L","journal-title":"J Am Acad Dermatol"},{"key":"14169_CR27","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1136\/ard.51.10.1159","volume":"51","author":"UN Verma","year":"1992","unstructured":"Verma UN, Singh RR, Misra R, Naik S, Agarwal SS (1992) Scleromyxoedema with features of systemic sclerosis. Ann Rheum Dis 51:1159\u20131161. https:\/\/doi.org\/10.1136\/ard.51.10.1159","journal-title":"Ann Rheum Dis"},{"key":"14169_CR28","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1093\/rheumatology\/33.9.872","volume":"33","author":"AL Taylor","year":"1994","unstructured":"Taylor AL, Owen ET (1994) Scleromyxoedema associated with synovitis and myopathy. Br J Rheumatol 33:872\u2013874. https:\/\/doi.org\/10.1093\/rheumatology\/33.9.872","journal-title":"Br J Rheumatol"},{"key":"14169_CR29","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S0190-9622(99)70383-X","volume":"41","author":"Z Bata-Csorgo","year":"1999","unstructured":"Bata-Csorgo Z, Husz S, Foldes M et al (1999) Scleromyxedema. J Am Acad Dermatol 41:343\u2013346. https:\/\/doi.org\/10.1016\/S0190-9622(99)70383-X","journal-title":"J Am Acad Dermatol"},{"key":"14169_CR30","doi-asserted-by":"publisher","first-page":"481","DOI":"10.4065\/74.5.481","volume":"74","author":"D Rayson","year":"1999","unstructured":"Rayson D, Lust JA, Duncan A, Su WP (1999) Scleromyxedema: a complete response to prednisone. Mayo Clin Proc 74:481\u2013484. https:\/\/doi.org\/10.4065\/74.5.481","journal-title":"Mayo Clin Proc"},{"key":"14169_CR31","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1067\/mjd.2000.104001","volume":"43","author":"RK Lister","year":"2000","unstructured":"Lister RK, Jolles S, Whittaker S et al (2000) Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg). J Am Acad Dermatol 43:403\u2013408. https:\/\/doi.org\/10.1067\/mjd.2000.104001","journal-title":"J Am Acad Dermatol"},{"key":"14169_CR32","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1046\/j.1365-2133.2001.04027.x","volume":"144","author":"D Launay","year":"2001","unstructured":"Launay D, Hatron PY, Delaporte E, Hachulla E, Devulder B, Piette F (2001) Scleromyxedema (lichen myxedematosus) associated with dermatomyositis. Br J Dermatol 144:359\u2013362. https:\/\/doi.org\/10.1046\/j.1365-2133.2001.04027.x","journal-title":"Br J Dermatol"},{"key":"14169_CR33","first-page":"36","volume":"70","author":"PV Prasad","year":"2004","unstructured":"Prasad PV, Joseph JM, Kaviarasan PK, Viswanathan P (2004) Scleromyxedema with subclinical myositis. Indian J Dermatol Venereol Leprol 70:36\u201338","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"14169_CR34","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1468-3083.2008.02766.x","volume":"23","author":"MY Wu","year":"2009","unstructured":"Wu MY, Hong JB, Yang CC, Hu SL, Liao YH (2009) Scleromyxedema with myopathy was successfully treated by thalidomide. J Eur Acad Dermatol Venereol 23:189\u2013190. https:\/\/doi.org\/10.1111\/j.1468-3083.2008.02766.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"14169_CR35","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1111\/j.1365-2230.2010.03807.x","volume":"35","author":"E Tan","year":"2010","unstructured":"Tan E, Lau N, Yung A (2010) Scleromyxoedema: a cause for unexplained encephalopathy and myositis. Clin Exp Dermatol 35:746\u2013748. https:\/\/doi.org\/10.1111\/j.1365-2230.2010.03807.x","journal-title":"Clin Exp Dermatol"},{"key":"14169_CR36","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1159\/000356469","volume":"5","author":"M Dolenc-Voljc","year":"2013","unstructured":"Dolenc-Voljc M, Jurcic V, Hocevar A, Tom\u0161ic M (2013) Scleromyxedema with subcutaneous nodules: successful treatment with thalidomide and intravenous immunoglobulin. Case Rep Dermatol 5:309\u2013315. https:\/\/doi.org\/10.1159\/000356469","journal-title":"Case Rep Dermatol"},{"key":"14169_CR37","first-page":"13","volume":"38","author":"KV Vysakha","year":"2019","unstructured":"Vysakha KV, Poyuran R, Nair SS, Nair M (2019) An unusual presentation of scleromyxedema as inflammatory myopathy. Acta Myol 38:13\u201316","journal-title":"Acta Myol"},{"key":"14169_CR38","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/neup.12659","volume":"40","author":"Y Yanagihara","year":"2020","unstructured":"Yanagihara Y, Hayashi S, Koge J et al (2020) Immunotherapy-refractory vacuolar myopathy with mucin deposition in scleromyxedema: a possible role of fibroblast growth factor 2. Neuropathology 40:492\u2013495. https:\/\/doi.org\/10.1111\/neup.12659","journal-title":"Neuropathology"},{"key":"14169_CR39","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1111\/ene.16008","volume":"30","author":"P Soontrapa","year":"2023","unstructured":"Soontrapa P, Tracy JA, Gonsalves WI, Liewluck T (2023) Treatment-responsive glycogen storage myopathy in a patient with POEMS syndrome: a new monoclonal gammopathy-associated myopathy. Eur J Neurol 30:3404\u20133406. https:\/\/doi.org\/10.1111\/ene.16008","journal-title":"Eur J Neurol"},{"key":"14169_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-025-08847-x","volume":"26","author":"Q de Berny","year":"2025","unstructured":"de Berny Q, Salle V, Renard C et al (2025) Vacuolar myopathy associated with lambda light chain myeloma: a case report and review of the literature. BMC Musculoskelet Disord 26:615. https:\/\/doi.org\/10.1186\/s12891-025-08847-x","journal-title":"BMC Musculoskelet Disord"},{"key":"14169_CR41","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.nmd.2023.06.010","volume":"33","author":"G Spagni","year":"2023","unstructured":"Spagni G, Modoni A, Primiano G et al (2023) Clinical, neurophysiological and serological clues for the diagnosis of neuromyotonia and distinction from cramp-fasciculation syndrome. Neuromuscul Disord 33:636\u2013642. https:\/\/doi.org\/10.1016\/j.nmd.2023.06.010","journal-title":"Neuromuscul Disord"},{"key":"14169_CR42","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.nmd.2007.06.002","volume":"17","author":"W M\u00fcller-Felber","year":"2007","unstructured":"M\u00fcller-Felber W, Horvath R, Gempel K et al (2007) Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients. Neuromuscul Disord 17:698\u2013706. https:\/\/doi.org\/10.1016\/j.nmd.2007.06.002","journal-title":"Neuromuscul Disord"},{"key":"14169_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2025.578608","volume":"404","author":"A Mazzeo","year":"2025","unstructured":"Mazzeo A, Cerulli Irelli E, Morano A, Quarato P, Di Gennaro G, Di Bonaventura C (2025) Rasmussen encephalitis and localized scleroderma of the lower limb: another piece of the puzzle. A case-report and literature review with individual participant data. J Neuroimmunol 404:578608. https:\/\/doi.org\/10.1016\/j.jneuroim.2025.578608","journal-title":"J Neuroimmunol"},{"key":"14169_CR44","first-page":"837","volume":"16","author":"M Ferrarini","year":"1989","unstructured":"Ferrarini M, Helfrich DJ, Walker ER, Medsger TA Jr, Whiteside TL (1989) Scleromyxedema serum increases proliferation but not the glycosaminoglycan synthesis of dermal fibroblasts. J Rheumatol 16:837\u2013841","journal-title":"J Rheumatol"},{"key":"14169_CR45","first-page":"171","volume":"12","author":"M Yaron","year":"1985","unstructured":"Yaron M, Yaron I, Yust I, Brenner S (1985) Lichen myxedematosus (scleromyxedema) serum stimulates hyaluronic acid and prostaglandin E production by human fibroblasts. J Rheumatol 12:171\u2013175","journal-title":"J Rheumatol"},{"key":"14169_CR46","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/jdv.16136","volume":"34","author":"F Kalli","year":"2020","unstructured":"Kalli F, Cioni M, Parodi A et al (2020) Increased frequency of interleukin-4 and reduced frequency of interferon-\u03b3 and IL-17-producing CD4+ and CD8+ cells in scleromyxedema. J Eur Acad Dermatol Venereol 34:1092\u20131097. https:\/\/doi.org\/10.1111\/jdv.16136","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"14169_CR47","doi-asserted-by":"publisher","first-page":"e362","DOI":"10.1016\/S2665-9913(21)00348-9","volume":"4","author":"A Marinkovic","year":"2022","unstructured":"Marinkovic A, Zypchen LN, Chan J, Chen LY, Parkin S (2022) Monoclonal gammopathy of clinical significance: what the rheumatologist needs to know. Lancet Rheumatol 4:e362\u2013e373. https:\/\/doi.org\/10.1016\/S2665-9913(21)00348-9","journal-title":"Lancet Rheumatol"},{"key":"14169_CR48","doi-asserted-by":"publisher","first-page":"e507","DOI":"10.1212\/WNL.0000000000004923","volume":"90","author":"Y Allenbach","year":"2018","unstructured":"Allenbach Y, Arouche-Delaperche L, Preusse C et al (2018) Necrosis in anti-SRP+ and anti-HMGCR+ myopathies: role of autoantibodies and complement. Neurology 90:e507\u2013e517. https:\/\/doi.org\/10.1212\/WNL.0000000000004923","journal-title":"Neurology"},{"key":"14169_CR49","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/ana.410410121","volume":"41","author":"JP Louboutin","year":"1997","unstructured":"Louboutin JP, Villanova M, Lucas-H\u00e9ron B, Fardeau M (1997) X-linked vacuolated myopathy: membrane attack complex deposition on muscle fiber membranes with calcium accumulation on sarcolemma. Ann Neurol 41:117\u2013120. https:\/\/doi.org\/10.1002\/ana.410410121","journal-title":"Ann Neurol"},{"key":"14169_CR50","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00401-026-03044-z","volume":"151","author":"CA Suarez","year":"2026","unstructured":"Suarez CA, Pittman SK, Inoue M et al (2026) VMA21 deficiency leads to autophagic dysregulation and altered vesicle trafficking in X-linked myopathy with excessive autophagy. Acta Neuropathol 151:73. https:\/\/doi.org\/10.1007\/s00401-026-03044-z","journal-title":"Acta Neuropathol"},{"key":"14169_CR51","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s004010100434","volume":"103","author":"C Fernandez","year":"2002","unstructured":"Fernandez C, Figarella-Branger D, Alla P, Harl\u00e9 JR, Pellissier JF (2002) Colchicine myopathy: a vacuolar myopathy with selective type I muscle fiber involvement. An immunohistochemical and electron microscopic study of two cases. Acta Neuropathol 103:100\u2013106. https:\/\/doi.org\/10.1007\/s004010100434","journal-title":"Acta Neuropathol"},{"key":"14169_CR52","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a041565","volume":"17","author":"A Franco-Romero","year":"2025","unstructured":"Franco-Romero A, Sandri M, Schiaffino S (2025) Autophagy in skeletal muscle. Cold Spring Harb Perspect Biol 17:a041565. https:\/\/doi.org\/10.1101\/cshperspect.a041565","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"14169_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24601-y","volume":"12","author":"A Zehender","year":"2021","unstructured":"Zehender A, Li YN, Lin NY et al (2021) TGF\u00df promotes fibrosis by MYST1-dependent epigenetic regulation of autophagy. Nat Commun 12:4404. https:\/\/doi.org\/10.1038\/s41467-021-24601-y","journal-title":"Nat Commun"},{"key":"14169_CR54","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.bbrc.2013.11.066","volume":"443","author":"K Tashiro","year":"2014","unstructured":"Tashiro K, Shishido M, Fujimoto K et al (2014) Age-related disruption of autophagy in dermal fibroblasts modulates extracellular matrix components. Biochem Biophys Res Commun 443:167\u2013172. https:\/\/doi.org\/10.1016\/j.bbrc.2013.11.066","journal-title":"Biochem Biophys Res Commun"},{"key":"14169_CR55","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.15252\/emmm.201404190","volume":"6","author":"J Guan","year":"2014","unstructured":"Guan J, Mishra S, Qiu Y et al (2014) Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity. EMBO Mol Med 6:1493\u20131507. https:\/\/doi.org\/10.15252\/emmm.201404190","journal-title":"EMBO Mol Med"},{"key":"14169_CR56","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002300","author":"T Mah\u00e9vas","year":"2020","unstructured":"Mah\u00e9vas T, Arnulf B, Bouaziz JD et al (2020) Plasma cell-directed therapies in monoclonal gammopathy-associated scleromyxedema. Blood. https:\/\/doi.org\/10.1182\/blood.2019002300","journal-title":"Blood"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-14169-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-14169-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-14169-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T10:08:38Z","timestamp":1793268518000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-14169-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":56,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["14169"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-14169-2","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"18 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: due to Table 1 was incomplete in the article.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the principles of the Declaration of Helsinki. In accordance with French regulations, additional approval from an ethics committee was not required for the secondary research use of diagnostic biological samples and associated clinical data, provided that patient consent was obtained.","order":2,"name":"Ethics","label":"Ethics approval statement and patient consent statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. No material from other sources requiring permission for reproduction was used in this manuscript.","order":3,"name":"Ethics","label":"Permission to reproduce material from other sources","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Clinical trial registration","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"633"}}